Market closed
Viridian Therapeutics/$VRDN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Ticker
$VRDN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
94
Website
VRDN Metrics
BasicAdvanced
$1.5B
-
-$4.26
1.11
-
Price and volume
Market cap
$1.5B
Beta
1.11
52-week high
$25.21
52-week low
$11.40
Average daily volume
1.6M
Financial strength
Current ratio
18.551
Quick ratio
18.21
Long term debt to equity
3.206
Total debt to equity
3.289
Interest coverage (TTM)
-108.20%
Management effectiveness
Return on assets (TTM)
-32.14%
Return on equity (TTM)
-51.88%
Valuation
Price to revenue (TTM)
3,880.567
Price to book
2.17
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-5.936
Growth
Revenue change (TTM)
-12.97%
Earnings per share change (TTM)
-16.48%
3-year revenue growth (CAGR)
-52.42%
3-year earnings per share growth (CAGR)
-39.46%
What the Analysts think about VRDN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
VRDN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VRDN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VRDN News
AllArticlesVideos
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Seeking Alpha·1 month ago
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Seeking Alpha·1 month ago
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1.5B as of January 30, 2025.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of January 30, 2025.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.